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Cognitive/affective and somatic/affective symptoms
of depression in patients with heart disease
and their association with cardiovascular
prognosis: a meta-analysis
R. de Miranda Azevedo*, A.M. Roest, P.W. Hoen and P. de Jonge
Department of Psychiatry, University Medical Center Groningen, University of Groningen, The Netherlands
Background. Several prospective longitudinal studies have suggested that somatic/affective depressive symptoms, but
not cognitive/affective depressive symptoms, are related to prognosis in patients with heart disease, but ﬁndings have
been inconsistent. The aim of this study was to investigate the association of cognitive/affective and somatic/affective
symptoms of depression with cardiovascular prognosis in patients with heart disease using a meta-analytic perspective.
Method. A systematic search was performed in PubMed, EMBASE and PsycInfo. Thirteen prospective studies on symp-
tom dimensions of depression and cardiovascular prognosis fulﬁlled the inclusion criteria, providing data on a total
of 11128 subjects. The risk estimates for each dimension of depressive symptoms, demographic and methodological
variables were extracted from the included articles.
Results. In least-adjusted analyses, both the somatic/affective [hazard ratio (HR) 1.30, 95% conﬁdence interval (CI)
1.19–1.41, p<0.001] and cognitive/affective (HR 1.07, 95% CI 1.00–1.15, p=0.05) dimensions of depressive symptoms
were associated with cardiovascular prognosis. In fully adjusted analyses, somatic/affective symptoms were signiﬁcantly
associated with adverse prognosis (HR 1.19, 95% CI 1.10–1.29, p<0.001) but cognitive/affective symptoms were not
(HR 1.04, 95% CI 0.97–1.12, p=0.25). An increase of one standard deviation (±1 s.D.) in the scores of the somatic/affective
dimension was associated with a 32% increased risk of adverse outcomes (HR 1.32, 95% CI 1.17–1.48, p<0.001).
Conclusions. Somatic/affective depressive symptoms were more strongly and consistently associated with mortality and
cardiovascular events in patients with heart disease compared with cognitive/affective symptoms. Future research
should focus on the mechanisms by which somatic/affective depressive symptoms may affect cardiovascular prognosis.
Received 25 September 2013; Revised 14 December 2013; Accepted 19 December 2013; First published online 27 January 2014
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Introduction
Major depression is common in patients with heart
disease, with a prevalence of around 20% following
acute myocardial infarction (MI) (Thombs et al. 2006).
However, the interpretation of the prognostic role of
depression in patients with heart disease is still subject
to debate. Two meta-analyses found that depression
was related to a 2- to 2.5-fold increased risk of
mortality and cardiovascular events in MI and heart
disease patients (Barth et al. 2004; van Melle et al.
2004). Nevertheless, it has also been reported that ad-
justment for cardiovascular disease severity and other
disease-speciﬁc risk factors was often incomplete in
individual studies (Nicholson et al. 2006). Thus, it is
unknown to what extent depression is a truly indepen-
dent prognostic risk factor, or one that is confounded
by cardiovascular disease severity (Nicholson et al.
2006).
It has been hypothesized that the type of de-
pression in patients with heart disease is not the same
as in the general psychiatric population. Ormel & de
Jonge (2011) suggested an integrative model in which
two prototypical forms of depression would com-
prise depression in patients with heart disease. These
forms differ in terms of etiology and prognosis: a
cognitive/affective subtype, marked by psychosocial
vulnerability (e.g. avoidant coping, neuroticism, stress
vulnerability), and a somatic/affective subtype, charac-
terized by vascular disease [e.g. atherosclerosis,
inﬂammation markers, sickness behavior, and deregu-
lation of the hypothalamic–pituitary–adrenal (HPA)
axis]. This model has been supported by ﬁndings
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from prospective longitudinal studies that investigated
speciﬁc dimensions of depressive symptoms and their
association with cardiovascular prognosis. In most of
these studies, two symptom dimensions were dis-
tinguished: cognitive/affective (e.g. pessimism, guilt
and self-dislike) and somatic/affective (e.g. insomnia,
fatigue and work difﬁculty) depressive symptoms
(Irvine et al. 1999; Roest et al. 2011). However, other
distinctions were also made, such as including an
appetitive dimension (de Jonge et al. 2006). A signiﬁ-
cant association between somatic/affective symptoms
of depression and cardiovascular mortality among
MI patients, even after adjustment for somatic health
status, was reported by de Jonge et al. (2006). By con-
trast, cognitive/affective depressive symptoms were
not predictive of adverse outcomes. The same pattern
of ﬁndings was reported in other studies in MI patients
and patients with acute coronary syndrome (Martens
et al. 2010; Roest et al. 2011). However, two studies in
patients undergoing coronary artery bypass graft
(CABG) surgery reported an association of cognitive/
affective but not somatic/affective symptoms of de-
pression with cardiovascular mortality (Connerney
et al. 2010) and recurrent cardiovascular events (Tully
et al. 2011).
In a narrative review on this topic by Carney &
Freedland (2012), although most studies reported that
somatic/affective symptoms were stronger predictors
of adverse cardiovascular prognosis than cognitive/
affective symptoms, the authors state that it is not yet
possible to come to a conclusion. Several sources of
bias were suggested, such as methodological inconsis-
tencies across the studies (factor analytic techniques
and covariate adjustments) and response bias (social
acceptability of reporting somatic/affective symptoms
versus cognitive/affective symptoms of depression).
Most importantly, however, the literature on this
issue lacks a systematic approach combining the exist-
ing evidence. The aim of the current study was there-
fore to investigate whether cognitive/affective and
somatic/affective depressive symptoms are differen-
tially associated with cardiovascular prognosis. We
conducted a meta-analysis of prospective longitudinal
studies assessing the association of cognitive/affective
and somatic/affective depressive symptoms in patients
with heart disease with cardiovascular prognosis.
Method
Inclusion criteria
The current study followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (Liberati et al. 2009) and the
Meta-Analysis Of Observational Studies in Epidemi-
ology (MOOSE) proposal for reporting (Stroup et al.
2000). The inclusion criteria were derived from four
relevant characteristics of the studies examined, re-
garding patient group, depressive symptoms, out-
comes and study design.
(1) Type of patients. Patients had to be diagnosed
with one of the following conditions: coronary
heart disease (CHD), acute coronary syndrome,
myocardial ischemia, congestive heart failure, or
MI. Studies focusing on patients who underwent
CABG surgery or cardioverter deﬁbrillator implan-
tation were also included. One study with subjects
with (suspected) myocardial ischemia, of whom
39.3% had a history of cardiovascular disease,
was also included (Linke et al. 2009).
(2) Measurement of depressive symptoms. Depressive
symptoms had to be measured using valid and
reliable instruments (interviews or self-reports),
after being diagnosed with one of the conditions
listed in inclusion criteria (1). Moreover, dimen-
sions of cognitive/affective and somatic/affective
depressive symptoms had to be identiﬁed.
(3) Prognostic outcomes. End-points had to contain
cardiovascular mortality, all-cause mortality or cardio-
vascular events (e.g. rehospitalization, stroke,
congestive heart failure).
(4) Study design. Studies had to be prospective (a cohort
or intervention study), with a minimum follow-up
time of 12 months. Only studies presenting original
data were included.
Identiﬁcation of studies
We used four strings of free terms that we screened
for in titles and abstracts of studies available in the
literature. The ﬁrst string represented the patient
group: Cardiac OR Heart OR Myocard*. The second
string represented depressive symptoms: Depress*.
The third string described the dimensions of depress-
ive symptoms: Somatic OR Cognitive OR Fatigue.
The fourth string represented the outcomes: Mortality
OR Prognos*. The literature search was performed
in the electronic databases EMBASE, PubMed and
PsycINFO, following previous work (Barth et al.
2004; van Melle et al. 2004; Nicholson et al. 2006). The
results of this search included all studies previously
reviewed by Carney & Freedland (2012), validating
our search strategy. No limits regarding language
and year of publication were applied. We also hand
searched other systematic reviews and meta-analyses
on the association between depression and heart dis-
ease. In the case of two studies reporting on the
same sample, we selected the one most comparable
to the rest of the studies (based on the questionnaire
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used and the objectives of the study). The literature
search was performed on 4 January 2013. The complete
search strategy is available in the online Supple-
mentary Material.
The selection of studies was performed by two inde-
pendent raters (R.deM.A. and A.M.R.) in two steps.
The ﬁrst step consisted of screening titles and abstracts
obtained from the systematic search. Potentially
relevant studies were included in the second step,
which consisted of full text reading. The level of agree-
ment between raters is represented by Cohen’s
κ coefﬁcient.
Data extraction
The following data were extracted from the included
studies: number of participants (sample size and per-
centage lost to follow-up), country, year of baseline
assessment, percentage of males, mean age, mean or
median duration of follow-up, labels of depressive
symptom dimensions, method to generate the symp-
tom dimensions, covariates used in the multivariate
analyses, end-points, effect estimates [e.g. hazard
ratios (HRs) and odds ratios (ORs)] and occurrence of
the end-point. To pool the studies, we selected the
analyses with the lowest number of covariates for the
least-adjusted models and with the highest number
of covariates in the fully adjusted models. In cases
where more than two dimensions of depressive symp-
toms were reported in one study, we selected the two
dimensions most comparable to the dimensions of the
other studies. To check whether the dimensions were
similar with regard to individual items, we listed the
way these symptoms loaded at each dimension across
the studies.
Statistical analyses
The overall meta-analysis consisted of pooling the ef-
fect sizes (HRs and ORs) for both cognitive/affective
and somatic/affective symptoms dimensions. As not
every study reported unadjusted results, we conducted
least-adjusted and fully adjusted analyses. If the same
study reported on multiple end-points, the hierarchy
for inclusion in the overall analysis was: cardiovascular
mortality, all-cause mortality, and cardiovascular
events. Heterogeneity was assessed with the I2 index:
a value of 25% implies a small degree of heterogeneity,
a value of 50% a moderate degree, and 75% a large
degree (Higgins et al. 2003). Because signiﬁcant hetero-
geneity across methods of individual studies (different
end-points, questionnaires and patient groups) was
expected, a random-effects model was chosen a priori
rather than a ﬁxed-effects model, as the ﬁrst takes
into account the within- and between-study variation
of the distribution (DerSimonian & Laird, 1986).
To aid the interpretability of the pooled effect
size, we performed a subgroup analysis of studies
that calculated their risk statistic using ±1 standard
deviation (±1 s.D.) rather than arbitrary values in the
depressive symptoms dimensions subscales. To cal-
culate this, we used the following formula, where
HRi is the hazard ratio associated with a symptom
dimension i, SDi is the standard deviation of the
symptom dimension score and Ui is the unit of
the associated risk (e.g. per one-point increase in the
dimension score) (Davidson et al. 2001):
exp{ln[HR]i × SDi/Ui}.
Subgroup analyses were planned a priori and were
based on: end-points (all-cause mortality, cardio-
vascular mortality, and cardiovascular events), patient
group (MI patients), assessment of depressive symp-
toms [Beck Depression Inventory – I (BDI-I); Beck &
Steer, 1987] and covariate adjustment (studies that
adjusted and studies that did not adjust simul-
taneously for both dimensions of depressive symp-
toms). Subgroup analyses were performed on fully
adjusted results.
One study reported results for two independent
arms (drug versus placebo), and it was therefore in-
cluded twice (once for each arm). In one study, cogni-
tive/affective and somatic/affective symptoms were
included as dichotomous variables (Schiffer et al.
2009). To keep in line with the other studies, the
authors provided us with the results including both
dimensions as continuous variables. As not every
author reported their results with the risk associated
with a 1 s.D. increase in the symptom dimension, we
requested means and standard deviations for the
dimensions that were not reported in the manuscripts.
One author provided us with the means and standard
deviations for each dimension of depressive symptoms
(Connerney et al. 2010).
To assess the agreement on symptom assignment
to one of the two dimensions, a multi-rater κ coefﬁcient
was estimated for the BDI-I (Light, 1971). To get a con-
servative estimate, loss of appetite and weight loss
were considered as cognitive/affective items for
speciﬁc studies in which these items were excluded
or included in a third dimension. Although loss of
appetite and weight loss were not considered as
cognitive/affective symptoms in any of the studies,
we classiﬁed these items as cognitive/affective in
these cases to avoid the possibility of overestimating
the coefﬁcient of agreement.
The possible presence of publication bias was
examined using three different approaches: visual
assessment of the funnel plot, Egger’s regression
approach, and the trim-and-ﬁll method (Soeken &
Sripusanapan, 2003). A funnel plot consists of a
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scatterplot displaying the effect sizes of individual
studies on the horizontal axis and the standard error
of the effect sizes on the vertical axis. If publication
bias is absent, the display should be comparable to a
funnel. In case it is asymmetrical, with studies appar-
ently missing on the lower left side of the scatterplot,
publication bias is likely to be present. Comprehensive
Meta-Analysis version 2.2 (Borenstein et al. 2005) was
used to perform the analyses.
Results
A ﬂow diagram of the literature search is displayed in
Fig. 1. The agreement between raters was good to very
good (Brennan & Silman, 1992). Cohen’s κ was 0.82 for
the ﬁrst step and 0.79 for the second step. A total of 14
studies met our inclusion criteria. However, as the
authors of one study could not provide the conﬁdence
intervals (CIs) of the effect estimate, this study could
not be included in the analyses (Barefoot et al.
2000). Hence a total of 13 studies were included in
the meta-analysis, providing data on 11128 patients.
The characteristics of these studies are displayed
in Table 1. The results of the separate studies are
presented in Table 2.
Dimensions of depressive symptoms
Among the 13 included studies, 10 used the BDI-I
questionnaire to measure symptoms of depression
(Irvine et al. 1999; Frasure-Smith & Lesperance, 2003;
de Jonge et al. 2006; Linke et al. 2009; Schiffer et al.
2009; Connerney et al. 2010; Martens et al. 2010; Roest
et al. 2011; Bekke-Hansen et al. 2012; van den Broek
et al. 2013). The following items were found to rep-
resent a cognitive/affective dimension: sadness (80%),
pessimism (90%), sense of failure (100%), dissatis-
faction (70%), guilt (100%), self-punishment (100%),
self-dislike (100%), self-accusations (100%), suicidal
ideation (100%), crying (70%), irritability (50%), social
withdrawal (90%), indecisiveness (70%) and change
in body image (50%). The individual symptoms
(work difﬁculty, insomnia, fatigability, somatic pre-
occupation and loss of libido) were considered somatic/
affective symptoms in all studies that used the
BDI-I. Loss of appetite was regarded as a somatic/
affective symptom in 80% of the studies, but in one
of the studies it loaded higher on a third ‘appetitive’
dimension (de Jonge et al. 2006). The other study
used the same division proposed by de Jonge et al.
(2006), and therefore this item was not included in
the analyses (Schiffer et al. 2009). The item weight
loss was also regarded as appetitive in one study
(de Jonge et al. 2006), was not included in another
study (Schiffer et al. 2009) and did not load on either
a cognitive/affective or somatic/affective dimension in
two studies (Martens et al. 2010; Bekke-Hansen et al.
2012). The agreement on BDI-I symptom assignment
to one of the two dimensions across studies was mod-
erate (κ=0.60) (Light, 1971; Conger, 1980).
Only one study used BDI-II (Tully et al. 2011) and
yielded a three-factor solution (cognitive, affective
and somatic symptoms). Two studies (Smolderen
et al. 2009; Hoen et al. 2010) assessed depressive symp-
toms with the nine-item Patient Health Questionnaire
(PHQ-9). In both studies, two dimensions were de-
rived from previous knowledge based on a conﬁr-
matory factor analysis on this questionnaire (de Jonge
et al. 2007): a cognitive dimension consisting of de-
pressed mood, lack of interest, worthlessness, concen-
tration problems and suicidal ideation; and a somatic
dimension consisting of appetite problems, sleeping
difﬁculties, psychomotor agitation or retardation, and
fatigue.
Adjustment for covariates across individual studies
All individual studies reported adjusted results. How-
ever, measures used to adjust for cardiovascular dis-
ease severity or medical co-morbidity diverged con-
siderably between studies. Ten studies (77%) adjusted
for left ventricular ejection fraction (LVEF), 10 (77%)
for history of MI, nine (69%) for co-morbid diabetes,
ﬁve (38%) for CHF and three (23%) for Killip class.
Least-adjusted overall meta-analysis
The pooled HR indicated that both the cognitive/
affective (HR 1.07, 95% CI 1.00–1.15, p=0.05) and
somatic/affective (HR 1.30, 95% CI 1.19–1.41, p<0.001)
dimensions of depressive symptoms were signiﬁ-
cantly associated with cardiovascular prognosis. The
forest plots of the overall analyses for each dimension
are presented in Fig. 2. High levels of heterogeneity
were found in both dimensions (cognitive/affective:
I2=71%; somatic/affective: I2=78%). Eight studies
provided unadjusted estimates, two adjusted for age
and sex, one for age only, one included both symp-
tom dimensions in the model, and two only reported
fully adjusted analyses.
Fully adjusted overall meta-analysis
The pooled HR indicated that cognitive/affective
symptoms were not (HR 1.04, 95% CI 0.97–1.12,
p=0.247) but somatic/affective symptoms were (HR
1.19, 95% CI 1.10–1.29, p<0.001) signiﬁcantly associ-
ated with cardiovascular prognosis. Moderate hetero-
geneity was found in the results for both dimensions
of depressive symptoms (cognitive/affective: I2=66%;
somatic/affective: I2=67%).
2692 R. de Miranda Azevedo et al.
Subgroup analyses
Subgroup analyses are displayed in Table 3. In gen-
eral, the subgroups indicated the same pattern
of ﬁndings: only somatic/affective symptoms were
associated with cardiovascular prognosis. However,
in a subgroup of studies that did not simultaneously
adjust for both dimensions, cognitive/affective
Fig. 1. Flow chart of the systematic search.
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ICD 591 62.7 80.7 Netherlands,
2003




MI 2442 60.8 56.2 USA, 1996 N.A. BDI-I C v. S PCA 2.3a Cardiovascular mortality, all-cause mortality
and cardiovascular events (non-fatal MI)
Tully, 2011 CABG 222 63.0 83.2 Australia,
1999
N.A. BDI-II AF v. C v. S CFA 4.9b Composite of cardiovascular events and
mortality (fatal or non-fatal MI, unstable
angina pectoris, repeat revascularization,
heart failure, sustained arrhythmia, stroke
or cerebrovascular accident, left ventricular
failure and mortality)
Roest, 2011 ACS 874 62.0 65.5 Canada, 1997 1.2 BDI-I C v. S PCA 1.0c All-cause mortality
Hoen, 2010 CHD 1019 67.0 82.0 USA, 2000 <1 PHQ-9 C v. S Prior study
(CFA)
6.0c Composite of cardiovascular events and
mortality (heart failure, MI, stroke, transient
ischemic attack or death)
Connerney,
2010
CABG 309 63.1 67.0 USA, 1997 N.A. BDI-I C v. S ODBS 9.3b Cardiovascular mortality
Martens, 2010 MI 419 59.0 78.0 Netherlands,
2003
0.0 BDI-I C v. S PCA 2.8 Composite of cardiovascular events (non-fatal
MI) and mortality
Schiffer, 2009 CHF 357 65.6 71.6 Netherlands,
2003
0.0 BDI-I C v. S Prior study
(CFA)
3.1 All-cause mortality
Linke, 2009 S MIS 550 58.4 0.0 USA, 1996 12.5d BDI-I C v. S PCA 5.8b Composite of cardiovascular events and
mortality (congestive heart failure, stroke,
MI and mortality)
Smolderen, 2009 MI 2347 59.1e 67.9 USA, 2003 0.0f PHQ-9 C v. S Prior study
(CFA)
4.0c,g All-cause mortality and rehospitalization
de Jonge, 2006 MI 494 60.6 81.0 Netherlands,
1997
6.4 BDI-I AP v. C v. S CFA 2.5 Cardiovascular mortality and cardiovascular
events (unstable angina, recurrent MI,
sustained arrhythmia, heart failure,












symptoms were also associated with cardiovascular
prognosis.
Publication bias
There were no indications for publication bias con-
cerning the association between the cognitive/affective
dimension and prognosis. However, the funnel plots
of the results for the somatic/affective dimension
showed an asymmetrical distribution of the studies
in both least-adjusted and fully adjusted models
(Online Supplementary Fig. S1) and the results of
Egger’s regression intercept conﬁrmed this asymmetry
(least-adjusted: p=0.01, two-tailed; fully adjusted:
p=0.01, two-tailed). After imputing ﬁve possible miss-
ing studies using the trim-and-ﬁll method, the pooled
effect size decreased, but the association between the
somatic/affective dimension and cardiovascular pro-
gnosis remained statistically signiﬁcant (least-adjusted:
HR 1.17, 95% CI 1.07–1.28, p<0.001; fully adjusted:
HR 1.11, 95% CI 1.02–1.21, p<0.001).
Discussion
Main ﬁndings
This is the ﬁrst meta-analysis to assess the association
of cognitive/affective and somatic/affective symptom
dimensions of depression with cardiovascular prog-
nosis in patients with heart disease using data from
13 studies. Both dimensions of depressive symptoms
were associated with adverse outcomes. However, in
the fully adjusted analysis, only somatic/affective
symptoms of depression, and not cognitive/affective
symptoms, were signiﬁcantly associated with an
increased risk of adverse outcomes. To reduce bias
due to heterogeneity across studies, several subgroup
analyses were performed. The results did not differ
by end-point. All except one of the fully adjusted sub-
group analyses demonstrated the same pattern of as-
sociation: only somatic/affective depressive symptoms
predicted adverse prognosis. Even in the subgroup
of studies that did not adjust for both dimensions,
where cognitive/affective symptoms were signiﬁcantly
associated with cardiovascular prognosis, the somatic/
affective dimension showed a stronger effect. An in-
crease of±1 s.D. in the somatic/affective dimension
was associated with a 32% increased risk of adverse
cardiovascular outcomes in the fully adjusted model.
Most depressive symptoms consistently loaded on
the same symptom dimension across individual
studies (e.g. guilt, self-punishment and self-dislike in
the cognitive/affective dimension, and work difﬁculty,
insomnia and fatigue in the somatic/affective dimen-
sion). However, a minority of symptoms loaded indis-
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Table 2. Overview of the associations of cognitive/affective (C) and somatic/affective (S) symptoms of depression and cardiovascular prognosis
First author, year Adjustment End-point
Occurrence
of end-point
(%) Point estimate (95% CI) Adjustment Point estimate (95% CI)
van den Broek,
2013
Unadjusted All-cause mortality 16.2 C: HR 1.02 (0.98–1.07)a Age, sex, relationship, secondary





shocks, C symptoms of depression
and S symptoms of depression
C: HR 0.97 (0.91–1.03)a
S: HR 1.14 (1.07–1.20)a S: HR 1.13 (1.04–1.23)a
Cardiovascular mortality 11.7 C: HR 1.02 (0.97–1.08)b C: HR 0.93 (0.87–1.00)b
S: HR 1.18 (1.10–1.25)b S: HR 1.21 (1.11–1.33)b
Bekke-Hansen,
2012
Treatment group All-cause mortality 13.7 C: HR 0.79 (0.70–0.90)a Treatment group, age, sex, ethnicity,
marital status, education, household
income and low perceived social
support
C: HR 0.94 (0.83–1.07)
S: HR 1.41 (1.26–1.58)a S: HR 1.24 (1.10–1.40)
Cardiovascular mortality 8.5 C: HR 0.84 (0.72–0.98)b C: HR 0.99 (0.84–1.16)
S: HR 1.36 (1.18–1.58)b S: HR 1.21 (1.03–1.41)
Non-fatal MI (cardiovascular
event)
13.8 C: HR 1.00 (0.90–1.13)a C: HR 1.05 (0.93–1.18)
S: HR 1.30 (1.16–1.46)a S: HR 1.25 (1.10–1.41)
Treatment group, age, sex, ethnicity, marital
status, education, household income, low
perceived social support, history of CHF,
LVEF and previous MI
All-cause mortality 13.7 C: HR 0.95 (0.84–1.09) Treatment group, age, sex, ethnicity,
marital status, education, household
income, low perceived social
support, history of CHF, LVEF,
previous MI, pulmonary disease,
diabetes, malignancy and renal
disease
C: HR 0.93 (0.82–1.06)a
S: HR 1.14 (1.01–1.29) S: HR 1.09 (0.96–1.24)a
Cardiovascular mortality 8.5 C: HR 1.00 (0.85–1.18) C: HR 0.98 (0.83–1.16)b
S: HR 1.09 (0.93–1.28) S: HR 1.05 (0.89–1.23)b
Non-fatal MI (cardiovascular
event)
13.8 C: HR 1.05 (0.93–1.18) C: HR 1.05 (0.93–1.18)a
S: HR 1.21 (1.07–1.37) S: HR 1.16 (1.03–1.32)a
Tully, 2011 Age, AF, C and S symptoms of depression,




29.3 AF: HR 0.76 (0.55–1.05)
C: HR 1.36 (1.02–1.82)b
S: HR 1.18 (0.82–1.70)b
Roest, 2011 C and S symptoms of depression All-cause mortality 5.8 C: OR 0.87 (0.66–1.16)b Age, diabetes, sex, Killip class,
previous MI, C and S symptoms
of depression
C: OR 1.07 (0.75–1.52)b
S: OR 2.01 (1.52–2.65)b S: OR 1.92 (1.36–2.71)b
Hoen, 2010 Age Composite of cardiovascular
events and mortality
39.2 C: HR 1.12 (1.03–1.21) Age, sex, diabetes, history of MI,
history of stroke, history of CHF,
LVEF, BMI, smoking, aspirin use,
beta-blocker use, statin use and
renin–angiotensin system
inhibitor use
C: HR 1.08 (0.99–1.17)b
S: HR 1.21 (1.11–1.31) S: HR 1.14 (1.05–1.24)b
Connerney, 2010 Unadjusted Cardiovascular mortality 20.1 C: HR 1.10 (1.03–1.17)b Age, gender, LVEF and diabetes C: HR 1.10 (1.03–1.17)b










Martens, 2010 Unadjusted Composite of cardiovascular
events and mortality
11.7 C: HR 1.17 (0.94–1.44)b C and S symptoms of depression C: HR 1.03 (0.81–1.32)a,b,c
S: HR 1.39 (1.08–1.79)b S: HR 1.37 (1.03–1.82)a
Previous MI and LVEF Composite of cardiovascular
events and mortality
11.7 C: HR N.A.
S: HR 1.31 (1.02–1.69)b
Schiffer, 2009 Unadjusted All-cause mortality 18.6 C: HR 1.20 (0.98–1.46)b,d Age, LVEF, NYHA class III/IV,
smoking, kidney disease, nitrates,
work status, C and S symptoms
of depression
C: HR 1.03 (0.77–1.37)b,d
S: HR 1.40 (1.12–1.76)b,d S: HR 1.26 (0.92–1.71)b,d
Linke, 2009 C and S symptoms of depression Composite of cardiovascular
events and mortality
16.5 C: HR 0.79 (0.62–1.02)b C and S symptoms of depression,
angiographic severity scores,
percutaneous coronary intervention,
CABG, CHF, MI, cerebrovascular
disease and peripheral vascular
disease
C: HR 0.87 (0.68–1.11)
S: HR 1.71 (1.36–2.14)b S: HR 1.63 (1.28–2.08)
C and S symptoms of depression, angiographic
severity scores, percutaneous coronary
intervention, CABG, CHF, MI,
cerebrovascular disease, peripheral vascular




16.5 C: HR 0.81 (0.64–1.03)b
S: HR 1.39 (1.08–1.79)b
Smolderen, 2009 Unadjusted All-cause mortality 18.1 (overall) C: HR 1.01 (0.89–1.14)b Age, sex, race, diabetes, prior coronary
artery disease, stroke, chronic renal
failure, chronic lung disease, CHF,
non-skin cancer, current smoking,
BMI, marital status, education,
insurance status, working status,
ST elevation AMI, LVEF 440%,
heart rate, angiography,
revascularization, percentage and
number of quality of care indicators
received
C: HR 1.10 (0.97–1.25)b
S: HR 1.22 (1.08–1.39)b S: HR 1.07 (0.94–1.21)b
Cardiovascular events 36.4 (overall) C: HR 1.01 (0.93–1.11)a C: HR 1.00 (0.91–1.09)a
S: HR 1.22 (1.11–1.33)a S: HR 1.16 (1.06–1.29)a
de Jonge, 2006 C and S symptoms of depression Cardiovascular mortality 4.3 AP: HR 1.30 (0.91–1.86) C and S symptoms of depression
LVEF<40%, Killip class52, previous
MI, AP symptoms of depression
AP: HR 0.94 (0.52–1.69)
C: HR 0.99 (0.61–1.62)b C: HR 0.40 (0.17–0.94)b
S: HR 1.64 (1.15–2.34)b S: HR 3.91 (1.83–8.39)b
Cardiovascular events 22.7 A: HR 1.16 (0.98 1.37) AP: HR 1.09 (0.88–1.37)
C: HR 1.15 (0.96–1.38)a C: HR 1.05 (0.79–1.41)a
S: HR 1.39 (1.15–1.67)a S: HR 1.30 (0.96–1.78)a
Frasure-Smith,
2003
Age and sex Cardiovascular mortality 13.9 C: HR 1.74 (1.41–2.14)b Age, sex, educational level, daily
smoking, previous MI, thrombolytic
treatment at index admission,
Q-wave MI, Killip class>1,
revascularization at index admission,
LVEF, hypoglycemic agents and
beta-blockers
C: HR 1.34 (1.12–1.61)b














and change in body image). Moreover, some symp-
toms could represent only one dimension in one
study and two dimensions simultaneously in another
study. Carney & Freedland (2012) suggested potential
causes for these inconsistencies, including differences
in the samples, analytic procedures and decision
rules. We consider that, despite of these inconsisten-
cies, the dimensions were sufﬁciently similar to pool
the studies.
Mechanisms
Several mechanisms may help to explain the dif-
ferential association between cognitive/affective and
somatic/affective depressive symptom dimensions
and cardiovascular prognosis. In the Heart and Soul
Study (de Jonge et al. 2007), lower heart rate variability
(HRV) was associated with a somatic/affective but
not with a cognitive/affective dimension of depressive
symptoms in heart disease patients. Similarly, somatic/
affective symptoms of depression were associated with
lower HRV and higher cortisol levels in healthy adoles-
cents (Bosch et al. 2009).
Inﬂammation may also play a role in the differential
association of depressive symptom dimensions and
cardiovascular prognosis. One study reported that
baseline scores on the cognitive/affective dimension
and changes in scores on the somatic/affective di-
mension were associated with soluble tumor necrosis
factor (TNF)-α receptor 2 (sTNFR2) in patients with
CHF (Kupper et al. 2012). Another study in post-MI
patients found that somatic/affective symptoms of de-
pression were signiﬁcantly associated with C-reactive
protein (CRP), white blood cell count (WBC) and
N-terminal pro-brain natriuretic peptide (NT-
proBNP) (Smolderen et al. 2012). Cognitive/affective
depressive symptoms were associated only with plate-
let counts. However, none of the dimensions explained
more than 1% of the variance of any of the biomarkers
(Smolderen et al. 2012). Although most studies in
populations with heart disease focused on the somatic/
affective and cognitive/affective symptom clusters,
other subtypes of depression were also used to in-
vestigate the association between depression and bio-
logical markers in the general psychiatric population.
Findings from The Netherlands Study of Depression
and Anxiety (NESDA) showed that patients with a
melancholic subtype of depression had higher levels
of awakening cortisol response compared to patients
with an atypical subtype of depression and healthy
controls. Nonetheless, patients with an atypical subtype
of depression had signiﬁcantly higher levels of inﬂam-
matory markers (CRP, interleukin-6 and TNF-α) and
markers of the metabolic syndrome, including large
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body mass index (BMI) and lower levels of high
density lipoprotein cholesterol (Lamers et al. 2013).
Limitations
The results of these analyses should be considered in
light of the study limitations. The quantiﬁed hetero-
geneity was moderate to high in almost all analyses
(Higgins et al. 2003). Several possible sources of hetero-
geneity across the literature were mentioned in the
study by Carney & Freedland (2012): the technique
used to derive the dimensions; factor loadings of indi-
vidual symptoms; covariate adjustment; and severity
of cognitive/affective versus somatic/affective symp-
toms of depression. The inclusion of different end-
points and patient groups might also have contributed
to the elevated quantiﬁed heterogeneity. There was
also substantial divergence on which covariates were
included in fully adjusted analyses across the studies,
partially because of the inclusion of different patient
groups.
All included studies provided adjustment for some
type of cardiovascular disease severity marker. LVEF
and previous MI were included in most studies
(77%) but other markers such as Killip class and medi-
cal co-morbidity were sometimes present. Adjustment
for cardiovascular disease severity may decrease the
strength of the association between depression and
cardiovascular outcomes (Nicholson et al. 2006; Meijer
et al. 2011). For example, a recent individual participant
data (IPD) meta-analysis in MI patients showed that
depression was associated with an increased risk
of 32% of all-cause mortality (Meijer et al. 2013a).
However, after adjustment for cardiac disease severity,
Fig. 2. Forest plot of the least-adjusted analysis of the cognitive/affective and somatic/affective dimensions.
CI, Conﬁdence interval.
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the association decreased by 29%. Thus, incomplete ad-
justment (i.e. residual confounding) for cardiac disease
severity markers could lead to biased estimates (Meijer
et al. 2013b). Therefore, we cannot exclude the possibility
that part of the association between somatic/affective
depressive symptoms and cardiovascular prognosis
could be explained by cardiovascular disease severity.
There are also indications of publication bias in our
dataset, which means that the association between
somatic/affective symptoms of depression with adverse
outcomes might be smaller than reported here. How-
ever, the results remained statistically signiﬁcant after
adjusting for this possible bias in both least-adjusted
and fully adjusted models.
In the majority of the studies examined (n=10), de-
pression was measured with the BDI-I self-report.
The BDI-I was updated to the BDI-II partly as a result
of potential inﬂation of the overall score due to the
inﬂuence of somatic illness on the somatic items
(Delisle et al. 2012). One of the main differences be-
tween the two versions of the BDI is that the BDI-II
excludes the items work difﬁculty, weight loss and so-
matic preoccupations. Delisle et al. (2012) showed that
MI patients had on average a score that was 3.4 points
higher than that for psychiatric patients matched on
age, sex and cognitive/affective scores when measured
with the BDI-I. In a similar report on the BDI-II,
somatic symptom scores were not higher among
post-MI patients in comparison to psychiatric out-
patients (Thombs et al. 2010). Therefore, we cannot
exclude the possibility that part of the association
between somatic depressive symptoms and cardio-
vascular prognosis could be explained by cardiovascu-
lar disease severity.





patients Adjustment HR (95% CI) p value I2 (%)
Risk per 1 s.D. 12 10494 Least adjusted C: 1.12 (1.01–1.24) 0.03 72
S: 1.44 (1.31–1.59) <0.001 68
Adjusted C: 1.06 (0.96–1.17) 0.25 65
S: 1.32 (1.17–1.48) <0.001 71
Studies reporting on all-cause mortality 5 6611 Least adjusted C: 1.01 (0.89–1.13) 0.93 79
S: 1.35 (1.17–1.56) <0.001 84
Adjusted C: 0.99 (0.93–1.04) 0.66 7
S: 1.17 (1.04–1.31) 0.008 64
Studies reporting on cardiovascular mortality 6 5340 Least adjusted C: 1.05 (0.95–1.16) 0.35 81
S: 1.23 (1.10–1.38) <0.001 82
Adjusted C: 1.02 (0.92–1.14) 0.68 80
S: 1.16 (1.04–1.30) 0.01 76
Studies reporting on cardiovascular events 7 7493 Least adjusted C: 1.06 (0.98–1.16) 0.14 56
S: 1.30 (1.20–1.39) <0.001 42
Adjusted C: 1.04 (0.97–1.11) 0.31 34
S: 1.17 (1.11–1.23) <0.001 0
Studies reporting on MI patients 6 7206 Least adjusted C: 1.04 (0.90–1.21) 0.57 80
S: 1.30 (1.12–1.51) 0.001 80
Adjusted C: 1.04 (0.92–1.18) 0.51 66
S: 1.18 (1.03–1.36) 0.02 74
Studies assessing depression with the BDI-I 10 7540 Least adjusted C: 1.06 (0.97–1.15) 0.19 75
S: 1.34 (1.20–1.50) <0.001 83
Adjusted C: 1.01 (0.92–1.10) 0.83 71
S: 1.23 (1.11–1.37) <0.001 74
Studies that adjusted for both depressive
symptom dimensions
8 4141 Adjusted C: 0.98 (0.87–1.10) 0.70 64
S: 1.28 (1.12–1.46) <0.001 71
Studies that did not adjust for both depressive
symptom dimensions
5 6987 Adjusted C: 1.10 (1.03–1.17) 0.003 39
S: 1.12 (1.03–1.22) 0.006 57
C, Cognitive/affective dimension; S, somatic/affective dimension; HR, hazard ratio; CI, conﬁdence interval;
MI, myocardial infarction; BDI-I, Beck Depression Inventory version I; S.D., standard deviation.
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Clinical implications
A meta-analysis by Baumeister et al. (2012) assessed
the effect of psychological and psychopharmacological
interventions in comparison to care as usual in
CHD patients with depression. The authors found a
small but clinically signiﬁcant effect on depression.
However, there were no indications that these inter-
ventions also improved cardiovascular prognosis.
Nevertheless, secondary analyses of the Enhancing
Recovery In Coronary Heart Disease (ENRICHD)
study showed that, in particular, decreases in somatic/
affective depressive symptoms were associated with
event-free survival among MI patients treated with
cognitive behavior therapy and concurrent antidepre-
ssant medication when necessary (Roest et al. 2013).
Currently, there are high expectations towards physi-
cal exercise as a potential treatment that could improve
both depression and cardiovascular prognosis, as it
could target speciﬁc biomarkers associated with ad-
verse prognosis in heart disease (Blumenthal et al.
2005; Blumenthal, 2008). Blumenthal et al. (2012) have
shown that physical activity signiﬁcantly reduced
depressive symptoms compared to placebo in CHD
patients. We conclude that the dimensions found
across the literature are comparable to the prototypical
subtypes of depression described by Ormel & de Jonge
(2011). Therefore, their treatment recommendations
for patients exhibiting higher levels of somatic/affective
depressive symptoms (e.g. promotion of health beha-
viors, compliance to cardiac rehabilitation programs)
should be further explored.
Recommendations for future research
Several meta-analyses have assessed the association
of depression and cardiovascular prognosis, indicating
the increasing number of individual studies on this
subject (Barth et al. 2004; van Melle et al. 2004;
Nicholson et al. 2006; Meijer et al. 2011). However, rela-
tively few studies have assessed the impact of speciﬁc
dimensions of depressive symptoms in the context of
heart disease. Thus, there are several cohorts where
these associations are yet to be explored. In addition,
designating the most appropriate technique to derive
symptom dimensions is warranted. Authors could
consider reporting distinct analyses for dimensions
yielded through different techniques. More research
is also needed to assess potential behavioral and bio-
logical mediators in the association between dimen-
sions of depressive symptoms and adverse medical
outcomes. Behavioral factors such as poor adherence
to medication, a high-fat diet, physical inactivity
and lack of social support have been shown to be
more prevalent among depressed patients than non-
depressed patients (Ziegelstein et al. 2000). Finally,
future studies could assess the differential associ-
ations of cognitive/affective and somatic/affective
depressive symptoms in an IPD meta-analysis, as this
approach can lead to more reliable estimates (Riley
et al. 2010).
Conclusions
Somatic/affective symptoms, but not cognitive/
affective symptoms, of depression were found to be
associated with cardiovascular prognosis in patients
with heart disease,. Although signiﬁcant heterogeneity
was found, the results seem to be robust in subgroup
analyses. Future research should focus on the mech-
anisms by which somatic/affective depressive symp-
toms may affect cardiovascular prognosis.
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